Optimizerx Corporation (OPRX)
NASDAQ:OPRX
Want to see OPRX full AI Analyst Report?
OPRX Stock Chart & Stats
$7.17
-$1.11(-19.07%)
At close: 4:00 PM EST
$7.17
-$1.11(-19.07%)
Day’s Range― - ―
52-Week Range$4.57 - $22.25
Previous CloseN/A
Volume200.46K
Average Volume (3M)466.73K
Market Cap
$98.14M
Enterprise Value$100.94M
Total Cash (Recent Filing)$20.17M
Total Debt (Recent Filing)$23.72M
Price to Earnings (P/E)14.4
Beta1.88
Next Earnings
Aug 06, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.36
Shares Outstanding18,765,076
10 Day Avg. Volume305,281
30 Day Avg. Volume466,727
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue0.94
Enterprise Value/Gross Profit1.36
Enterprise Value/Ebitda5.34
Forecast
1Y Price Target
$12.00Price Target Upside67.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.92
Revenue Forecast (FY)$109.34M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a sizable equity base provide durable financial flexibility. With minimal debt after recent paydowns and a new credit facility, OptimizeRx can absorb client churn, fund product investments or opportunistic M&A, and withstand cyclical headwinds without immediate refinancing pressure.
Sustained Margin ImprovementHigh gross margins and expanding adjusted EBITDA reflect structural improvements in cost of revenue and operating efficiency. These margins create a durable profitability foundation that supports reinvestment into product, funds longer sales cycles, and improves resilience versus revenue volatility over the next several quarters.
Product Traction & Recurring RevenueStrong DAP and subscription growth, plus 110% net revenue retention, indicate improving product-market fit and recurring revenue mix. This structural shift toward subscriptions and programmatic DSP integration increases revenue visibility and long-term monetization potential as healthcare digital promo budgets migrate to programmatic channels.
Bears Say
Top-line Weakness & Guidance CutA sustained decline in reported revenue and lower full-year guidance signal durable top-line pressure. Persistent revenue contraction reduces headroom for growth investments, complicates multi-quarter recovery, and forces management to prioritize margin preservation over market-share expansion absent clear demand recovery.
Contracted Revenue & Major Client DisruptionMaterial contracted revenue shortfalls and a cited large-account disruption create lasting visibility issues. Shorter contract durations and MFN-related pressures undermine revenue predictability and increase renewal risk, making multi-quarter revenue recovery dependent on resolving client execution issues and winning new durable contracts.
Cash Flow Volatility And FCF DeclineAlthough FCF and operating cash remain positive on a TTM basis historically, the recent decline and a negative quarter highlight liquidity sensitivity. Weaker cash generation constrains reinvestment in sales/product and increases reliance on revolver/term facility, raising execution risk during a multi-quarter revenue trough.
OptimizeRx News
OPRX FAQ
What was Optimizerx Corporation’s price range in the past 12 months?
Optimizerx Corporation lowest stock price was $4.57 and its highest was $22.25 in the past 12 months.
What is Optimizerx Corporation’s market cap?
Optimizerx Corporation’s market cap is $98.14M.
When is Optimizerx Corporation’s upcoming earnings report date?
Optimizerx Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 52 days.
How were Optimizerx Corporation’s earnings last quarter?
Optimizerx Corporation released its earnings results on May 12, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.053 by $0.087.
Is Optimizerx Corporation overvalued?
According to Wall Street analysts Optimizerx Corporation’s price is currently Undervalued.
Does Optimizerx Corporation pay dividends?
Optimizerx Corporation does not currently pay dividends.
What is Optimizerx Corporation’s EPS estimate?
Optimizerx Corporation’s EPS estimate is 0.1.
How many shares outstanding does Optimizerx Corporation have?
Optimizerx Corporation has 18,765,076 shares outstanding.
What happened to Optimizerx Corporation’s price movement after its last earnings report?
Optimizerx Corporation reported an EPS of $0.14 in its last earnings report, beating expectations of $0.053. Following the earnings report the stock price went down -22.476%.
Which hedge fund is a major shareholder of Optimizerx Corporation?
Currently, no hedge funds are holding shares in OPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OptimizeRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (67.36% Upside)
$12.00 (67.36% Upside)
Blogger Sentiment
Bullish
OPRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 206.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 17.0%
Last 30 Days ▼ 17.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.24%
12-Months-Change
Fundamentals
Return on Equity
5.47%
Trailing 12-Months
Asset Growth
-0.30%
Trailing 12-Months
Company Description
Optimizerx Corporation
OptimizeRx Corporation is a digital health technology firm delivering a broad spectrum of solutions to life sciences organizations, healthcare providers, and patients. Its core offerings encompass financial messaging and a virtual patient support hub, enabling healthcare providers to seamlessly access sample vouchers, co-pay assistance, and other patient support resources directly within their electronic medical records (EMR) or e-prescribing platforms. The company also facilitates brand awareness and therapeutic communication through various messaging services, including targeted ads and unbranded educational content. Additionally, OptimizeRx consults with pharmaceutical manufacturers, guiding them in devising and executing effective eRx media strategies, which involves drug file integration, sales force education, and comprehensive strategy development for product promotion. It operates a cloud-based Mobile Health Messenger platform, offering interactive health messaging to bolster medication adherence and improve care coordination. Furthermore, a HIPAA-compliant automated mobile messaging platform empowers pharmaceutical companies and associated entities to directly connect with patients, fostering better regimen compliance. Patient-centric programs provide essential treatment and affordability details, alongside lifestyle and condition trackers, internet device integration, and tools for forms and surveys. For healthcare professionals, the company offers an evidence-based physician engagement solution that leverages real-world data. This tool helps identify patients suitable for particular therapies, raises awareness of patient access routes, and detects early signs of non-adherence within patient groups. Another key offering is a therapy initiation workflow designed to expedite patient access to treatments, especially those requiring extensive medical documentation from healthcare providers before pharmacists can dispense prescribed medications. Established in 2006, OptimizeRx is headquartered in Rochester, Michigan.
OPRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging operational and margin progress (strong adjusted EBITDA growth, improved gross margins, significant product traction with DAP and subscription growth, refinancing savings, and KPI improvements) against tangible near-term top-line challenges (10% YoY revenue decline, 15-20% contracted revenue shortfall, a major client disruption, reduced cash and negative operating cash flow, and a downward revision to revenue guidance). Management emphasized these headwinds are short-to-intermediate term and highlighted programmatic/DSP initiatives and subscription mix as drivers for 2027 recovery.View all OPRX earnings summariesOPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(67.36% Upside)
Technical Analysis
Ownership Overview
7.57% Insiders
19.59% Mutual Funds
30.89% Other Institutional Investors
31.82% Public Companies and
Individual Investors